A contact carrier in cholera has which of the following characteristics?
Which geographical region is predominantly associated with HIV C subtype?
What is the presumptive treatment of malaria in a chloroquine-resistant area?
World Diabetes Day is celebrated on which date?
What is the best preventive measure against tetanus neonatorum?
What is the denominator used in calculating the General Fertility Rate?
Sputum from a patient is disinfected immediately following expectoration. This process is known as:
Metabolic Syndrome has the following features except?
Immunoprophylaxis of leprosy includes?
Which of the following statements is true for the Mantoux test?
Explanation: ### Explanation **Correct Answer: D. Duration of carrier state is less than 10 days** In Cholera, carriers are individuals who shed *Vibrio cholerae* in their stools but do not manifest clinical symptoms. They are classified based on the timing of their infection: 1. **Pre-epidemic/Incubatory carrier:** Sheds bacilli during the incubation period. 2. **Convalescent carrier:** A recovered patient who continues to shed bacilli (usually for 2–3 weeks). 3. **Contact (Healthy) carrier:** A person who has acquired the organism from a patient but never develops the disease. **Why Option D is correct:** The **Contact carrier** state is transient. These individuals typically shed the vibrios for a very short duration, usually **less than 10 days** (often only 2–5 days). **Analysis of Incorrect Options:** * **Option A:** Infection of the gallbladder is a hallmark of **Chronic carriers** (those shedding bacilli for >1 year). Chronic carriage is extremely rare in cholera (unlike Typhoid) and is not a feature of contact carriers. * **Option B:** By definition, a carrier is someone who harbors the infectious agent; therefore, their **stools must be positive** for *Vibrio cholerae* to be classified as such. * **Option C:** Carriers are epidemiologically significant because they outnumber cases (the "Iceberg Phenomenon"). Contact carriers play a **major role in the spread** of infection as they are mobile and asymptomatic. --- ### High-Yield Pearls for NEET-PG: * **Carrier to Case Ratio:** In El Tor cholera, the ratio is high (up to 100:1), whereas in Classical cholera, it is lower (around 4:1). * **Chronic Carrier:** Defined as shedding for >1 year; the most famous site of sequestration is the **gallbladder**. * **Incubation Period:** Very short, ranging from 1 to 5 days (average 2–3 days). This "short incubation period" contributes to the explosive nature of epidemics. * **Gold Standard Diagnosis:** Stool culture on **TCBS medium**.
Explanation: **Explanation:** The distribution of Human Immunodeficiency Virus (HIV) is characterized by significant genetic diversity, with **HIV-1 Group M** being responsible for the global pandemic. This group is further divided into several subtypes (clades). **1. Why India is Correct:** **Subtype C** is the most prevalent subtype of HIV-1 worldwide, accounting for nearly half of all global infections. It is the predominant strain in **India**, South Africa, and Ethiopia. In India, Subtype C is responsible for over 90% of HIV infections, making it a high-yield fact for community medicine and microbiology. **2. Analysis of Incorrect Options:** * **Europe and America (Options B & C):** These regions are predominantly associated with **Subtype B**. Most early research and clinical trials were conducted on this subtype, although other subtypes are now increasing due to migration. * **Thailand (Option D):** Southeast Asia, particularly Thailand, is uniquely associated with the **CRF01_AE** (a circulating recombinant form) and Subtype B. **High-Yield Clinical Pearls for NEET-PG:** * **Most common HIV type globally:** HIV-1. * **Most common HIV-1 Subtype globally and in India:** Subtype C. * **HIV-2 prevalence:** Primarily restricted to West Africa; in India, it is most commonly seen in Maharashtra and parts of Southern India. * **Transmission:** While Subtype B is often associated with MSM (men who have sex with men) in Western countries, Subtype C in India is primarily spread through **heterosexual transmission**. * **Diagnosis:** The "Window Period" for modern 4th generation ELISA (p24 antigen + antibody) is typically 14–21 days.
Explanation: **Explanation:** The management of malaria depends on the species involved and the local drug-resistance patterns. In areas where **Chloroquine resistance** is documented, the standard treatment for *Plasmodium falciparum* (or presumptive treatment where resistance is suspected) shifts to alternative regimens. **Why Option B is Correct:** The combination of **Sulphalene (or Sulfadoxine) and Pyrimethamine** (often referred to as the SP combination) acts as a sequential folate antagonist. This combination was historically the mainstay for presumptive treatment in chloroquine-resistant areas before the widespread adoption of ACT (Artemisinin-based Combination Therapy). Sulphalene acts on dihydropteroate synthase, while Pyrimethamine inhibits dihydrofolate reductase, providing a synergistic effect against resistant strains. **Analysis of Incorrect Options:** * **Option A (Chloroquine + Pyrimethamine):** Chloroquine is ineffective in resistant areas; adding pyrimethamine alone does not provide the necessary synergistic "sulfonamide" component required for efficacy. * **Option C (Chloroquine + Primaquine):** This is the standard treatment for *P. vivax* (Chloroquine for erythrocytic stages and Primaquine for hepatic stages/hypnozoites). It is ineffective against chloroquine-resistant *P. falciparum*. * **Option D (Sulphalene 1000 mg):** Monotherapy with sulfonamides is never recommended due to the rapid development of resistance and lower efficacy compared to the SP combination. **High-Yield Clinical Pearls for NEET-PG:** 1. **Current National Program (NVBDCP) Update:** While SP was the presumptive treatment, the current "Gold Standard" for *P. falciparum* in India is **ACT (Artemisinin-based Combination Therapy)**. 2. **North-East States:** In India’s NE states, due to SP resistance, the recommended ACT is **Artesunate + Pyronaridine** or **Artemether + Lumefantrine**, rather than AS+SP. 3. **Primaquine Contraindication:** Always screen for **G6PD deficiency** before administering Primaquine to avoid acute hemolysis. 4. **Pregnancy:** ACT is now considered safe in the 1st trimester (as per recent WHO/National guidelines), though historically Quinine was preferred.
Explanation: **Explanation:** **Correct Answer: C. November 14th** World Diabetes Day (WDD) is observed annually on **November 14th**. This date was chosen to mark the birthday of **Sir Frederick Banting**, who co-discovered insulin along with Charles Best in 1922. The campaign was established in 1991 by the International Diabetes Federation (IDF) and the WHO in response to the growing health threat posed by diabetes. In 2006, it became an official United Nations Day. The symbol for World Diabetes Day is the **Blue Circle**, representing the unity of the global diabetes community. **Analysis of Incorrect Options:** * **A. May 8th:** This is **World Red Cross Day** and World Thalassaemia Day. * **B. March 8th:** This is **International Women’s Day**. (Note: World Kidney Day is also observed in March, on the second Thursday). * **D. December 1st:** This is **World AIDS Day**, a frequently asked date in NEET-PG regarding communicable diseases. **High-Yield Clinical Pearls for NEET-PG:** * **Screening:** According to NPCDCS guidelines, opportunistic screening for Diabetes Mellitus starts at **30 years** of age. * **Diagnostic Criteria:** Fasting Plasma Glucose $\geq$ 126 mg/dL or HbA1c $\geq$ 6.5%. * **Rule of Halves:** Diabetes follows the "Rule of Halves"—half the people are diagnosed, half of those receive care, and half of those achieve treatment targets. * **Public Health Goal:** The primary prevention of Type 2 Diabetes focuses on lifestyle modifications (primordial prevention).
Explanation: **Explanation:** **1. Why Option A is Correct:** The primary strategy to prevent neonatal tetanus (Tetanus Neonatorum) is the **active immunization of the mother** with Tetanus Toxoid (TT) or Tetanus-diphtheria (Td) vaccine during pregnancy. This stimulates the production of maternal IgG antibodies, which cross the placenta to the fetus. These antibodies provide passive immunity to the newborn, protecting them during the high-risk period of umbilical cord healing (the first 28 days of life). **2. Why Other Options are Incorrect:** * **Option B (Passive immunization of the child):** Administering Tetanus Immune Globulin (TIG) to a newborn is a reactive measure for post-exposure prophylaxis (e.g., if born in unsterile conditions to an unimmunized mother). It is not the standard preventive public health strategy. * **Option C (Active immunization of the child):** The pediatric DPT/Pentavalent vaccine schedule starts at 6 weeks of age. Since neonatal tetanus occurs within the first month of life, the child is too young to develop their own active immunity in time. * **Option D (Passive immunization of the mother):** This provides only short-term protection for the mother and does not stimulate the sustained antibody production necessary for effective transplacental transfer to the fetus. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "3 Cleans" Rule:** Besides immunization, prevention relies on clean delivery, clean cord cutting, and clean cord care. * **Elimination Goal:** Neonatal tetanus is considered "eliminated" when the incidence is **<1 case per 1,000 live births** in every district. India achieved maternal and neonatal tetanus elimination (MNTE) in 2015. * **Vaccination Schedule:** Under the National Immunization Schedule (NIS), a pregnant woman receives 2 doses of Td (4 weeks apart) or 1 booster dose if she was vaccinated within the last 3 years. * **Incubation Period:** Neonatal tetanus typically presents between day 3 and day 14 of life (often called the "8th-day disease").
Explanation: ### **Explanation** The **General Fertility Rate (GFR)** is a more refined measure of fertility than the Crude Birth Rate (CBR) because it relates births to the specific segment of the population capable of childbearing. **1. Why Option C is Correct:** The GFR is defined as the number of live births per 1,000 women in the reproductive age group (usually 15–44 or 15–49 years) in a given year. By using the **mid-year population of women in the reproductive age group** as the denominator, the measure accounts for age and sex distribution, focusing only on those "at risk" of giving birth. * **Formula:** $\frac{\text{Number of live births in an area during the year}}{\text{Mid-year female population aged 15–49 years}} \times 1000$ **2. Why Other Options are Incorrect:** * **Option A (Live births):** This is typically the *numerator* for fertility and mortality indicators (like IMR or Maternal Mortality Ratio), not the denominator for GFR. * **Option B (Mid-year population):** This is the denominator for the **Crude Birth Rate (CBR)**. It is less accurate than GFR because it includes men, children, and elderly women who are not at risk of childbirth. * **Option D (Married women 15–45 years):** This is the denominator for the **General Marital Fertility Rate (GMFR)**. While GFR considers all women in the age group regardless of marital status, GMFR focuses strictly on married women. ### **High-Yield Clinical Pearls for NEET-PG** * **GFR vs. CBR:** GFR is generally **4 times higher** than the CBR because the denominator (women 15–49) is approximately one-fourth of the total population. * **Total Fertility Rate (TFR):** The average number of children a woman would have if she experiences current age-specific fertility rates through her reproductive years. It is the best indicator of overall fertility. * **Replacement Level Fertility:** A TFR of **2.1** is considered the replacement level where a population exactly replaces itself from one generation to the next. * **Net Reproduction Rate (NRR):** The number of daughters a newborn girl will bear. **NRR = 1** is the demographic goal for population stabilization.
Explanation: **Explanation:** The correct answer is **Concurrent Disinfection**. This refers to the immediate disinfection and disposal of infectious materials (such as sputum, urine, feces, or contaminated linen) throughout the course of an illness. The primary goal is to minimize the spread of the infectious agent from the patient to others by neutralizing the pathogen as soon as it leaves the body. **Analysis of Options:** * **Concurrent Disinfection (A):** This is the standard practice for active cases. By disinfecting sputum immediately after expectoration, the chain of transmission is broken in real-time. * **Pre-concurrent Disinfection (B):** This is not a standard epidemiological term used in infection control. * **Recurrent Disinfection (C):** This is a distractor term. While disinfection may happen repeatedly, the formal medical term for ongoing disinfection during illness is "concurrent." * **Terminal Disinfection (D):** This refers to the final disinfection of the patient’s room and personal belongings *after* the patient has recovered, been discharged, or died. It aims to ensure the environment is safe for the next occupant. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylactic Disinfection:** Refers to measures like chlorination of water or pasteurization of milk to prevent potential disease. * **Levels of Disinfection:** Remember that **Sterilization** kills all microbial life including spores, whereas **Disinfection** reduces the number of pathogens but may not eliminate bacterial spores. * **Common Disinfectants:** For sputum in TB cases, 5% Cresol or 1% Sodium Hypochlorite are frequently used. * **Key Distinction:** Concurrent = *During* the illness; Terminal = *After* the illness.
Explanation: **Explanation:** Metabolic Syndrome (also known as Syndrome X or Insulin Resistance Syndrome) is a cluster of metabolic abnormalities that significantly increase the risk of cardiovascular disease and Type 2 Diabetes Mellitus. **Why "High HDL levels" is the correct answer:** The hallmark of Metabolic Syndrome is **Dyslipidemia**, specifically characterized by **Low HDL (High-Density Lipoprotein) levels** (the "good" cholesterol). According to the NCEP ATP III criteria, HDL levels below 40 mg/dL in men or 50 mg/dL in women are considered a diagnostic component. Therefore, "High HDL" is protective and is not a feature of the syndrome. **Analysis of Incorrect Options:** * **A. High Triglycerides:** Hypertriglyceridemia (≥150 mg/dL) is a core component of the metabolic profile in these patients. * **B. High Blood Pressure:** Hypertension (≥130/85 mmHg) or being on antihypertensive medication is a primary diagnostic criterion. * **C. High Blood Sugar:** Impaired fasting glucose (≥100 mg/dL) or a diagnosis of Type 2 Diabetes is a key feature reflecting underlying insulin resistance. **High-Yield Clinical Pearls for NEET-PG:** * **NCEP ATP III Criteria:** Diagnosis requires at least **3 out of 5** of the following: 1. **Abdominal Obesity:** Waist circumference >102 cm (M) or >88 cm (F). *Note: For South Asians (Modified WHO criteria), it is >90 cm (M) and >80 cm (F).* 2. **Triglycerides:** ≥150 mg/dL. 3. **HDL Cholesterol:** <40 mg/dL (M) or <50 mg/dL (F). 4. **Blood Pressure:** ≥130/85 mmHg. 5. **Fasting Glucose:** ≥100 mg/dL. * The fundamental underlying pathophysiology is **Insulin Resistance**. * Metabolic Syndrome is a major risk factor for **Non-Alcoholic Fatty Liver Disease (NAFLD)** and **PCOS**.
Explanation: **Explanation:** The correct answer is **BCG (Bacillus Calmette–Guérin)**. **1. Why BCG is correct:** Although primarily used for Tuberculosis, the BCG vaccine provides significant cross-protection against *Mycobacterium leprae* due to shared antigenic determinants between *M. tuberculosis* and *M. leprae*. Meta-analyses suggest that a single dose of BCG offers approximately 50% protection against leprosy, and this protection increases significantly with a second (booster) dose. Under the National Leprosy Eradication Programme (NLEP), BCG is recognized for its immunoprophylactic role. **2. Analysis of Incorrect Options:** * **MMR:** This is a live attenuated vaccine for Measles, Mumps, and Rubella (viral infections) and has no efficacy against mycobacterial diseases. * **ICRC Bacillus:** While the ICRC vaccine (developed from a cultivable strain of *M. leprae* at the Indian Cancer Research Centre) is indeed an anti-leprosy vaccine, it is considered an **experimental/candidate vaccine** and is not used for routine immunoprophylaxis in the same capacity as BCG. * **Anthrax vaccine:** This is used for *Bacillus anthracis* and has no cross-reactivity with leprosy. **3. High-Yield Clinical Pearls for NEET-PG:** * **MIP Vaccine:** The **Mycobacterium Indicus Pranii (MIP)** vaccine is the world’s first exclusive vaccine for leprosy, developed in India. It is used as an adjunct to MDT and for immunoprophylaxis in close contacts. * **Chemoprophylaxis:** The drug of choice for post-exposure prophylaxis (PEP) in leprosy is a **Single Dose of Rifampicin (SDR)**. * **Combined Approach:** The most effective prevention for household contacts is currently a combination of BCG vaccination and SDR.
Explanation: **Explanation:** The Mantoux test (Tuberculin Skin Test) is a screening tool used to detect **latent tuberculosis infection (LTBI)** rather than active clinical disease. **1. Why Option C is Correct:** A positive Mantoux test indicates that the individual has been infected with *Mycobacterium tuberculosis* and has developed a Type IV (delayed-type) hypersensitivity reaction. However, it **cannot distinguish** between a latent infection and active clinical disease. Diagnosis of active TB requires clinical assessment, radiological findings, and microbiological confirmation (e.g., Sputum AFB or CBNAAT). **2. Analysis of Incorrect Options:** * **Option A:** The test must be read between **48 to 72 hours** after the intradermal injection of 5 TU (Tuberculin Units) of PPD. Reading before 48 hours may lead to false-negative results as the delayed hypersensitivity reaction takes time to peak. * **Option B:** An induration of **≥10 mm** is generally considered positive in the Indian context. Larger indurations (e.g., >15 mm) correlate with a higher risk of harboring a recent infection, but 6-9 mm is often considered "equivocal" or negative depending on the risk group. * **Option D:** This is epidemiologically incorrect. **Tuberculin reactors** (those already positive) represent the "pool of infection" from which the majority of new clinical cases emerge through endogenous reactivation. **High-Yield Clinical Pearls for NEET-PG:** * **Method:** 0.1 ml of PPD RT23 is injected intradermally on the volar aspect of the forearm (Mantoux technique). * **Measurement:** Only the **induration** (palpable hardening) is measured, not the erythema (redness). * **False Negatives:** Can occur in miliary TB, HIV/AIDS (low CD4 count), malnutrition, and recent viral infections (e.g., Measles). * **BCG Effect:** Previous BCG vaccination can cause a false positive, though the induration is usually smaller and wanes over time.
Epidemiology of NCDs
Practice Questions
Cardiovascular Disease Prevention
Practice Questions
Diabetes Control Program
Practice Questions
Cancer Screening and Control
Practice Questions
Chronic Respiratory Diseases
Practice Questions
Mental Health Program
Practice Questions
Blindness Control Program
Practice Questions
Accident and Injury Prevention
Practice Questions
NCD Risk Factor Surveillance
Practice Questions
National Program for Prevention and Control of Cancer, Diabetes, CVD, and Stroke
Practice Questions
Oral Health Program
Practice Questions
Geriatric Health Issues
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free